NASDAQ:AEZS

Aeterna Zentaris Stock Forecast, Price & News

$0.61
+0.00 (+0.10 %)
(As of 09/17/2021 03:15 PM ET)
Add
Compare
Today's Range
$0.59
$0.62
50-Day Range
$0.61
$0.85
52-Week Range
$0.29
$3.62
Volume1,753 shs
Average Volume8.56 million shs
Market Capitalization$74.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89
30 days | 90 days | 365 days | Advanced Chart
Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter.


Aeterna Zentaris logo

About Aeterna Zentaris

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

0.99 out of 5 stars

Medical Sector

1227th out of 1,351 stocks

Pharmaceutical Preparations Industry

600th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aeterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What stocks does MarketBeat like better than Aeterna Zentaris?

Wall Street analysts have given Aeterna Zentaris a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aeterna Zentaris wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Aeterna Zentaris' next earnings date?

Aeterna Zentaris is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Aeterna Zentaris
.

How were Aeterna Zentaris' earnings last quarter?

Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.60 million for the quarter. Aeterna Zentaris had a negative net margin of 161.21% and a negative trailing twelve-month return on equity of 15.42%.
View Aeterna Zentaris' earnings history
.

How has Aeterna Zentaris' stock been impacted by Coronavirus?

Aeterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AEZS stock has decreased by 9.5% and is now trading at $0.6149.
View which stocks have been most impacted by COVID-19
.

Who are Aeterna Zentaris' key executives?

Aeterna Zentaris' management team includes the following people:
  • Klaus Wolfgang Paulini, President, Chief Executive Officer & Director
  • Leslie Auld, Chief Financial Officer & Senior Vice President
  • Michael Teifel, Chief Scientific Officer
  • Nicola Ammer, Chief Medical Officer & VP-Clinical Development
  • Matthias Gerlach, Vice President-Manufacturing & Supply Chain

Who are some of Aeterna Zentaris' key competitors?

What other stocks do shareholders of Aeterna Zentaris own?

What is Aeterna Zentaris' stock symbol?

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Who are Aeterna Zentaris' major shareholders?

Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Susquehanna International Group LLP (0.00%), Natixis (0.18%), Virtu Financial LLC (0.15%), Goldman Sachs Group Inc. (0.14%), Renaissance Technologies LLC (0.09%) and Group One Trading L.P. (0.00%).

Which institutional investors are selling Aeterna Zentaris stock?

AEZS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, HAP Trading LLC, and Sabby Management LLC.

Which institutional investors are buying Aeterna Zentaris stock?

AEZS stock was bought by a variety of institutional investors in the last quarter, including Natixis, Goldman Sachs Group Inc., Susquehanna International Group LLP, Renaissance Technologies LLC, Group One Trading L.P., Simplex Trading LLC, Virtu Financial LLC, and Citadel Advisors LLC.

How do I buy shares of Aeterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $0.61.

How much money does Aeterna Zentaris make?

Aeterna Zentaris has a market capitalization of $74.59 million and generates $3.65 million in revenue each year.

How many employees does Aeterna Zentaris have?

Aeterna Zentaris employs 11 workers across the globe.

What is Aeterna Zentaris' official website?

The official website for Aeterna Zentaris is www.zentaris.com.

Where are Aeterna Zentaris' headquarters?

Aeterna Zentaris is headquartered at 315 Sigma Drive South Carolina, Summerville SC, 29486.

How can I contact Aeterna Zentaris?

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at (843) 900-3223 or via email at [email protected]


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.